EthnoPharm
Signed in as:
filler@godaddy.com
The global nutraceutical industry is a mostly plant-based $300 billion dollar industry with a forecasted 9.3% CAGR (2021-2028).
With its relatively low barriers to market entry, the nutraceutical market offers a strong and growing opportunity for development.
In the United States, representing the world’s largest nutraceutical market, innovation in nutraceutical ingredients presents the most attractive opportunity in development, as the market conditions are favorable, and the regulatory landscape puts the burden on brandholders with low market entry hurdles and risk-based regulations.
Yet, although the market for plant-derived ingredients continues to grow, our global biodiversity continues to be threatened. Extinctions are happening at the rate of 1,000 times the natural rate and an estimated 50% of all species may be extinct by 2050, mainly due to habitat loss (through human activity). Additionally,
approximately 30,000 species are used for medicinal and aromatic purposes, not even counting the functional foods that are also consumed; yet few have been developed with clinical research to offer sophisticated ethical nutraceuticals to the market.
With 80% of the world’s population currently relying on herbal medicines, the potential for clinical development of plant-based ingredients is significant. Moreover, their development will give value to threatened biodiversity, providing visibility and a basis for re-evaluating biodiverse land values. This shift towards a greater valuing of biodiversity can affect how land use is assessed and can also provide a basis for land conservation which can greater serve humanity and the ecosystem.
Through the cost-effective and targeted process of ingredient identification, research investment, market-ready scale-up, and brand development, EBI seeks to develop branded ingredients ready for the market. Ethnopharm and Kerry Hughes have spent the past couple decades researching and developing plant ingredients with innovative potential and have gathered them into the privately-held Ethnopharm Biodiversity Database (EBD).
Through the EBD, ingredients are identified that have high potential and low hurdles to development. A plan to market is developed and strategic partners and funding secured. Through the EBI, development of ingredients in a pipeline approach with appropriate clinical backing, proprietary standing and regulatory review is always in process. Engaging EBI can enable the development of ingredients from biodiversity in a significantly more time and cost-effective manner than currently practiced in the industry.
In parallel, EBI secures location-specific partnerships in order to develop ingredients which fulfill not only market demands, but also provides a basis for conservation of biodiverse ecosystems.
EBI is actively accepting partnership inquiries for ongoing development projects. We would love to hear from manufacturers/Brandhoders whoe are prepared to invest in long-term sustainable development of biodiversity in the quest for new natural product ingredients or finished products.
Alternatively, countries or townships with interest in development of biodiversity as a means for conservation and poverty alleviation with benefit-share agreements are can make good EBI partners.
Contact us through the Contact US form on this website and detail your inquiry.
Copyright © 2022 EthnoPharm - All Rights Reserved. This Site Contains Affiliate Links.
Powered by GoDaddy